Tips for Managing Anxiety with LEMS
Patients with Lambert-Eaton myasthenic syndrome (LEMS) can feel a loss of control over their lives after being diagnosed with a chronic disease. Dealing with ... Read more
Updates
-
-
‘LEMme Tell Ya’ Patient Stories in Their Own Words: Ashley Gregory
For the remainder of 2019, “LEMme Tell Ya” will feature a monthly series called “‘LEMme Tell Ya’ Patient Stories in Their Own Words.” The ... Read more -
Warning Signs of Depression in LEMS
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disease characterized by chronic fatigue and muscle weakness, among other symptoms. Fatigue and stress caused by ... Read more -
Not All Superheroes Wear Capes
I wasn’t diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) until my sons were grown. Upon his return from serving in the Navy, one of my ... Read more -
My Mental Health Safety Net
In my last column, I shared wording that I’ve used to explain Lambert-Eaton myasthenic syndrome (LEMS) to my family, friends, and medical providers. However, ... Read more
-
Tips for Making Every Doctor’s Visit Count When You Have LEMS
Managing treatment for a rare disease such as Lambert-Eaton myasthenic syndrome (LEMS) can be ... -
How Do You Tell Someone You Have a Disease They’ve Never Heard Of?
If you are like me, when you finally received a diagnosis of Lambert-Eaton myasthenic ... -
At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing
Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is ... -
Firdapse Active Ingredient 3,4‐DAP Targets Muscles in Rats, Has Long-Lasting Effect, Study Says
3,4‐diaminopyridine — the active ingredient of the only FDA-approved treatment for adults with Lambert-Eaton ... -
5 Tips for Developing a Treatment Plan for LEMS
Managing a rare disease like Lambert-Eaton myasthenic syndrome (LEMS) can be challenging. One thing ...
Subscribe to our mailing list
Get regular updates delivered to your email box.
Thanks! Please check your email for a confirmation email.
FDA Accepts Catalyst’s NDA for Firdapse with Priority Review Status for LEMS
News
The U.S. Food and Drug Administration has accepted Catalyst Pharmaceuticals’ new drug application (NDA) for Firdapse (amifampridine phosphate) for Lambert-Eaton myasthenic syndrome (LEMS), with priority review status. Firdapse is a formulation of amifampridine phosphate in development for the treatment of LEMS as ... Read more